QPPV.COM KNOWLEDGE ASSESSMENT

Monoclonal Antibodies: Biology, Development and Pharmacovigilance

Test your understanding of the concepts covered by Monoclonal Antibodies: Biology, Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is confounding particularly important when evaluating adverse events in patients receiving monoclonal antibodies for serious chronic diseases?

Underlying diseases and concomitant treatments can produce or modify symptoms and laboratory abnormalities that overlap with suspected reactions Serious diseases eliminate the possibility of medicine-related adverse events Concomitant medicines are not relevant once a biological medicine is administered Background morbidity affects only clinical trials, not post-authorisation data

Question 2 of 10 Why may the relationship between dose and exposure for a monoclonal antibody be nonlinear?

Because all parenteral products have unpredictable absorption Because target-mediated binding can contribute to elimination and vary with dose or target abundance Because monoclonal antibodies are converted into small molecules after administration Because pharmacodynamic biomarkers always increase proportionally with dose

Question 3 of 10 What is the most appropriate use of a known mechanism of action during signal evaluation?

To establish causality whenever the event is biologically plausible To replace the need for clinical and epidemiological evidence To generate and refine a safety hypothesis that must be assessed against the totality of evidence To classify the event automatically as a class effect

Question 4 of 10 Why can Fc engineering create new or modified pharmacovigilance considerations even when an antibody's antigen-binding region is unchanged?

The Fc region determines the antibody's brand name Fc modifications can alter receptor or complement interactions, persistence and immune effector activity Fc engineering prevents any interaction with normal tissues The Fc region affects only product packaging

Question 5 of 10 A patient experiences an adverse event after switching between two related biological products. What is the most appropriate assessment principle?

The switch caused the event because it was the most recent treatment change The event should be ignored because related products are scientifically similar The event requires reconstruction of treatment history and consideration of timing, alternatives and product-specific exposure Only the first product received should be recorded

Question 6 of 10 Why should apparent immunogenicity rates not be compared across studies without examining assay methods?

Because immunogenicity can only be measured in spontaneous reports Because assay sensitivity, specificity and design can affect the apparent detection rate Because all studies use identical assays by definition Because treatment duration has no influence on detection

Question 7 of 10 Which statement best describes the pharmacovigilance status of a biosimilar monoclonal antibody?

It can be treated as the same medicinal product as the reference medicine for all case processing Knowledge of the reference product can inform hypotheses, but the biosimilar remains a distinct medicinal product for pharmacovigilance Only the reference product requires batch traceability An adverse event after switching is automatically attributed to the biosimilar

Question 8 of 10 What is the purpose of maintaining an auditable evidence trail in monoclonal-antibody pharmacovigilance?

To ensure that every safety conclusion remains unchanged over time To allow reconstruction of the evidence, rationale, assessments and decisions leading to a safety conclusion To replace medical review with documented case counts To document only regulatory communications and not source information

Question 9 of 10 A patient develops toxicity after receiving the same nominal dose as before, but disease activity and target expression have changed. Which interpretation is most appropriate?

The dose is unchanged, so exposure must be unchanged The altered disease and target context could have changed target-mediated disposition and effective exposure The event cannot be drug-related because no dose increase occurred Only the administration route can influence exposure

Question 10 of 10 Which statement best describes the pharmacovigilance significance of humanised or fully human antibody sequences?

They eliminate the possibility of anti-drug antibodies They generally remove the need for immunogenicity assessment They may reduce some non-human sequence-related risks, but unwanted immune responses remain possible and context-dependent They guarantee equivalent immunogenicity across all products

Monoclonal Antibodies: Biology, Development and Pharmacovigilance

Cookie Settings